Table 4 Risk factors of pneumocystis carinii pneumonia according to rituximab treatment indication
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Non-rituximab group | Reference | Reference | ||
XM-positive | 0.69 (0.09–5.20) | 0.72 | 0.63 (0.08–4.78) | 0.66 |
ABO-incompatible | 2.49 (1.12–5.54) | 0.03 | 2.44 (1.09–5.48) | 0.04 |
ABO- incompatible and XM- positive | 1.67 (0.22–12.50) | 0.62 | 1.53 (0.20–11.54) | 0.68 |
Rejection treatment within 6 months after transplant | 91.9 (41.10–205.69) | < 0.01 | 77.61 (26.35–228.60) | < 0.01 |